Fig. 1: Nogo-B is overexpressed in NPC and correlates with a poor prognosis of NPC.

A Average expression level of Nogo was highly expressed in stage IV NPC tissues in the GSE102349 dataset. B The mRNA expression of Nogo-B was upregulated in the NPC cell lines (HK1, TW03, SUNE1, S26, 5–8 F, CNE2, and HONE1), as demonstrated by real-time PCR. C Western blotting showed that the expression of Nogo-B was upregulated in the NPC cell lines (HK1, TW03, SUNE1, S26, 5–8 F, CNE2, and HONE1). D The expression of Nogo-B was higher in NPC tissues (NPC) than in nontumorous tissues (NPN), as demonstrated by real-time PCR (P = 0.0184). E Representative IHC results from nontumorous tissues (left) and NPC tissues with different levels of Nogo-B protein, as detected by IHC. F The 3-year OS rate of 116 NPC patients was 85.3%. Kaplan–Meier and log-rank test analysis showed that the cumulative 3-year OS rate was 93.7% in the low Nogo-B expression group (blue line) and 75.5% in the high Nogo-B expression group (red line) (P = 0.003). G The 3-year PFS rate of 116 NPC patients was 84.5%. Kaplan–Meier and log-rank test analysis showed that the cumulative 3-year PFS rate was 93.7% in the low Nogo-B expression group (blue line) and 73.6% in the high Nogo-B expression group (red line) (P = 0.001).